Clinical efficacy of anti-IgE therapy for eosinophilic otitis media

Otology and Neurotology

Volumn 33, Issue 7, 2012, Pages 1218-1224

  Iino, Yukiko ^a   Hara, Mariko ^a   Hasegawa, Masayo ^a   Matsuzawa, Shingo ^a   Shinnabe, Akihiro ^a   Kanazawa, Hiromi ^a   Yoshida, Naohiro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti IgE therapy; Bronchial asthma; Eosinophilic otitis media; Immunoglobulin E; Omalizumab

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADULT; AGED; ARTICLE; EOSINOPHIL; FEMALE; HEARING TEST; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; SECRETORY OTITIS MEDIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; EOSINOPHILS; FEMALE; HEARING TESTS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; OTITIS MEDIA WITH EFFUSION; PILOT PROJECTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84865602775     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e318263d5b8     Document Type: Article

References (20)

1. Tomioka S, Yuasa R, Iino Y. Intractable otitis media in cases with bronchial asthma. In: Mogi G, Honjo I, Ishii T, Takasaka T, eds. Recent Advances in Otitis Media, Proceedings of the Second Extraordinary International Symposium on Recent Advances in Otitis Media. New York, NY: Kugler Publications, 1993:183-6.
2. Tomioka S, Kobayashi T, Takasaka T. Intractable otitis media in patients with bronchial asthma (eosinophilic otitis media). In: Sanna M, ed. Cholesteatoma and Mastoid Surgery. Rome, Italy: CIC Edizioni Internazionali, 1997:851-3.
3. Nagamine H, Iino Y, Kojima C, Miyazawa T, Iida T. Clinical characteristics of so-called eosinophilic otitis media. Auris Nasus Larynx 2002;29:19-28.
4. Iino Y, Nagamine H, Yabe T, Matsutani S. Eosinophils are activated in middle ear mucosa and middle ear effusion of patients with intractable otitis media associated with bronchial asthma. Clin Exp Allergy 2001;31:1135-43.
5. Nonaka M, Fukumoto A, Ozu C, et al. IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. Acta Otolaryngol 2003;123:383-7.
6. Iino Y, Kakizaki K, Katano H, Saigusa H, Kanegasaki S. Eosinophil chemoattractant in middle ear of patients with eosinophilic otitis media. Clin Exp Allergy 2005;35:1370-6.
7. Iino Y, Usubuchi H, Kodama K, et al. Eosinophilic inflammation in the middle ear induces deterioration of bone conduction hearing level in patients with eosinophilic otitis media. Otol Neurotol 2010; 31:100-4.
8. IinoY, Tomioka-Matsutani S, Matsubara A, Nakagawa T,Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx 2011;38:456-61.
9. Iino Y, Nagamine H, Kakizaki K, et al. Effectiveness of instillation of triamcinolone acetonide into middle ear for eosinophilic otitis media associated with bronchial asthma. Ann Allergy Asthma Immunol 2006;97:761-6.
10. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available from: http://www.ginathma.org. Accessed May 3, 2012.
11. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139:28-35.
12. Saini S, Rosen KE, Hsieh H-J, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.
13. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:68-71.
14. Vignola AM, Humbert M, Bousquer J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis SOLAR. Allergy 2004;7:709-17.
15. Grundmann SA, Hemfort PB, Luger TA, Brehler R. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 2008;121:257-8.
16. Menzella F, Piro R, facciolongo N, Castgnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patients with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011;7:9.
17. Massanari M, Holgate ST, Busse WW, et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010;104:188-96.
18. Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinopil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:1493-9.
19. Dal Negro RW, Guerriero M, Micheletto C, Ognella S, Visconti M. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study. J Asthma 2011;48: 437-41.
20. Iino Y, Usubuchi H, Kodama K, et al. Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma. Otol Neurotol 2008;29:949-52.